Edition:
United States

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

2.30USD
11:06am EDT
Change (% chg)

$0.03 (+1.32%)
Prev Close
$2.27
Open
$2.26
Day's High
$2.32
Day's Low
$2.26
Volume
25,081
Avg. Vol
62,206
52-wk High
$4.18
52-wk Low
$1.98

Latest Key Developments (Source: Significant Developments)

Endocyte Q4 loss per share $0.26
Friday, 10 Mar 2017 08:05am EST 

Endocyte Inc : Endocyte reports fourth quarter and year end 2016 financial results and provides clinical and pipeline update . Q4 loss per share $0.26 . Q4 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S . Endocyte inc- anticipates its cash balance at end of 2017 to be approximately $100 million . Endocyte inc- also anticipate receiving additional clinical data on ec1169 and ec1456, during 2017 .Endocyte inc- expect to file investigational new drug application for ec2629 in mid 2017.  Full Article

Endocyte plans to collaborate with Seattle Children's Research Institute
Friday, 10 Mar 2017 08:00am EST 

Endocyte Inc :Endocyte Inc - plan to collaborate with seattle children's research institute and Dr. Michael Jensen for development of Endocyte's SMDC platform.  Full Article

Endocyte reports Q2 loss per share $0.33
Thursday, 4 Aug 2016 04:01pm EDT 

Endocyte Inc : Q2 loss per share $0.33 . Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S . Endocyte reports second quarter 2016 financial results .Company revised guidance for its expected cash balance at end of 2016 to be above $130 million.  Full Article

Endocyte announces Final Overall Survival Results From Phase 2b TARGET Trial in Non-Small Cell Lung Cancer Patients
Monday, 7 Sep 2015 02:45pm EDT 

Endocyte:Says the final overall survival (OS) analysis from the Phase 2b TARGET trial evaluating its small molecule drug conjugate (SMDC) vintafolide in combination with docetaxel in patients with FR positive recurrent NSCLC at the World Conference on Lung Cancer in Denver, Colorado.Vintafolide plus docetaxel improved overall survival by 2.7 months in NSCLC regardless of histology (Median OS 11.5 vs. 8.8 months, OS HR=0.86, 95% CI [0.58, 1.26]).In the predefined subset analysis of patients with adenocarcinoma, which expresses higher levels of folate receptor, vintafolide plus docetaxel improved OS by 5.9 months (12.5 vs. 6.6 months, HR=0.72, 95% CI [0.44, 1.16]).OS for vintafolide as single agent was similar to docetaxel (OS 8.4 vs. 8.8 months, HR=1.02, 95% CI [0.70, 1.50]).EC1456 is a second generation folate-targeted SMDC, which delivers a more potent drug payload at higher doses than vintafolide.  Full Article

More From Around the Web

BRIEF-Endocyte Inc presents data at AACR identifying multiple methods for managing severe side effects resulting from car t-cell treatment

* Endocyte Inc - presents data at AACR identifying multiple methods for managing severe side effects resulting from car t-cell treatment